First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
Crossref DOI link: https://doi.org/10.1007/s00280-015-2703-1
Published Online: 2015-03-05
Published Print: 2015-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Avisar, Noa
Adar, Liat
Bock, Jason
Müller, Udo
Shen, David
Barash, Steve
Pukac, Laurie
Text and Data Mining valid from 2015-03-05